The clinical trials below are available in the specialty you selected. Choose a different specialty.
A First-in-Human Study of the Safety of Single Continuous Intravenous Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers
Healthy men and women of non-childbearing potential are needed to participate in a research study to assess the safety and tolerability of an investigational drug that is being developed for the treatment of heart failure. (REF# 51256)
Development of Prognostic Platelet RNA Biomarkers to Tailor Antiplatelet Therapy
Healthy volunteers and people with Type 2 Diabetes are needed to participate in an aspirin research study at the Duke Clinical Research Unit. The study will evaluate the effect of aspirin and ticagrelor (an antiplatelet agent similar to aspirin) on the genomic profiles of whole blood and platelets.
Study participation will involve 5 or 6 visits to the DCRU over the course of approximately 5 months. The aspirin & ticagrelor therapy for participants will last 16 weeks. Financial compensation is provided for participation. (REF# 00048621)
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 in Subjects with Moderate to Severe Ulcerative Colitis
Men and women between the ages of 18 & 65 with a diagnosis of ulcerative colitis may participate in a research study for an investigational drug, which has been developed as a potential therapy to reduce the inflammation and tissue damage associated with a colitis flare without suppressing the patient's immune system. (REF# 00048410)
A Randomized, 4-Sequence, Double-Blind Study to Test the Safety of Combined Dosing with Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude
Healthy volunteers are needed to participate in a research study that will assess the safety, tolerability, and beneficial effects of a study drug combination being tested for possible use in high altitude sickness. Eligible participants will be healthy men and women, 18 to 50 years of age, who weigh at least 143 pounds, take no medications, and are non-smokers. (REF# 37605)
A randomized, double-blind, placebo controlled study to assess the efficacy of LCQ908 on cardiovascular risk
This study is a proof of concept to determine if an investigational drug called LCQ908 can reduce triglyceride levels and lessen cardiovascular risk in people with cardiovascular disease. (REF# 35097)